Star adds $200M after spinout successes

Star adds $200M after spinout successes is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Gwendolyn Wu · 2026-10-23

Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

Source: BioPharma Dive